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Considering that there is limited information on interaction between age and effects of the 
opioid system and glucocorticoids in determination of the level of anxiety, we examined the 
influences of 1 mg/kg dexamethasone and 20 mg/kg RU486 (as an agonist and an antagonist 
of glucocorticoid receptors), and also of  5 mg/kg morphine and 20 mg/kg naloxone (as an 
agonist and an antagonist of the opioid system) on the anxiety level in young and mature male 
Wistar rats.  The percentage of time in the open arms in the plus-maze test was evaluated as 
an index of anxiety behavior, and the percentage of number of entries in the closed arms was 
measured as an index of locomotor activity. The results showed that morphine (5 mg/kg) 
and dexamethasone (1 mg/kg) exerted anxiolytic effects in both young and mature rats, 
while only in young rats these agents reduced locomotor activity. RU486 could prevent the 
anxiolytic effect of morphine, and the anxiolytic effect of dexamethasone was inhibited by 
naloxone in young animals but this was not observed  in mature rats. These results showed 
that there is  an interactive effect between glucocorticoids and the opioid system in mediation 
of anxiety, and the respective events are age-dependent.
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INTRODUCTION
The stress system coordinates adaptive responses 
of the organism to a great variety of stressors [1-
3]. One of the main components of the stress system 
is the hypothalamo-pituitary-adrenal (HPA) axis; 
corticotrophin-releasing hormone (CRH) and locus 
ceruleus-produced norepinephrine (NE) play important 
roles in realization of the stress responses [1, 2]. 
Activation of the stress system leads to behavioral and 
peripheral autonomic changes improving the ability of 
the organism to adjust homeostasis and increasing its 
chances for survival [2, 3].  End hormones of the HPA 
axis, glucocorticoids, perform a number of roles in 
the organism [3]. There is evidence that disregulation 
of the HPA axis is significantly implicated in various 
pathophysiological disorders, like anxiety [4, 5]. 
Some studies have shown that acute injections of low 
doses of glucocorticoids, dexamethasone (DEX) in 
particular, reduce the anxiety level, while in higher 
doses this intensifies this phenomenon in animals [6].
It has been demonstrated that opioid receptor 
agonists and antagonists, such as morphine and 
naloxone,  considerably influence anxiety in animals 
[7-9].On the other hand, some studies showed that 
the opioid system can intensely  affect the HPA axis 
activity [6, 10].
It has been shown that dexamethasone is able to 
modify the effects of opioids in the analgesia and 
anxiety studies, in such a way indicating for important 
interaction between glucocorticoids and activity of the 
opioid system [7, 11, 12].
Acute activation of opioid receptors increases the 
activity of the HPA axis, leading to intensification 
of the release of ACTH and corticosterone in rats 
[11, 13].The pituitary-adrenocortical response to 
mild stress was markedly stronger in juveniles 
exposed to morphine than in adult individuals [14]. 
Morphine may either increase the perceived severity 
of the action of stressors or decrease the sensitivity 
to negative feedback effects of stress on the levels 
of corticosterone in juvenile males [14]. There is 
a striking shift in the morphine effects on the HPA 
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axis across development [14]. An opioid receptor 
antagonist, naloxone, can inhibit the anxiolytic effect 
of glucocorticoids, like dexamethasone (DEX) [7].
Several variables (including age) are known to 
influence the anxiety levels [15, 16, 17]. It has been 
shown that anxiety in adolescents is less intense 
than that in adults [18]. There are some evidences 
that glucocorticoids can change various types of 
behavior depending on the age [19, 20], but there 
were no evidence about interrelations between age and 
anxiolytic effects of opiates or glucocorticoids. 
In this study, we investigated the interaction between 
activities of the opioidergic and glucocorticoid 
systems whith respect to in anxiety-related behaviors 
in young and mature male rats. 
METHODS
Animals and Treatments. The experiments were car­
ried out on 98 male Wistar rats. 49 young (1-month-
old individuals weighing 40-45 g) and 49 mature 
(3-month-old ones weighing 170-180 g). Animals 
were kept at a constant temperature (22 ± 2°C) and a 
12-h light/dark cycle with free access to food and wa­
ter. The rats were handled 4-5 days before the tests. 
All experiments were done within the light phase 
(9 to 11 a.m.).
Animals were divided into 14 groups. Young and 
mature rats received (i) saline, (ii) 5 mg/kg morphine 
[1], (iii) 1 mg/kg DEX [21], (iv) 2.5 mg/kg morphine + 
+ 1 mg/kg DEX,  (v)  5 mg/kg morphine + 1 mg/kg 
DEX, (vi)  20 mg/kg RU486 (mifepristone a 
glucocorticoid antagonist) [22] + 5 mg/kg morphine, 
and (vii) 2 mg/kg naloxone + 1 mg/kg DEX. The use 
of effective doses of medication in this our study was 
based on the results of previous studies. 
Drugs. Morphine (Temad Co., Iran), DEX (Iran 
Hormone Co., Iran), naloxone (Tolidaru Co., Iran), 
and RU486 (Sigma, USA) were dissolved in saline. All 
drugs were injected i.p. in a volume of 5 cm3 saline/kg.
Elevated Plus-Maze Test. The elevated plus maze 
set was made of wood with two open arms (50 × 5 cm) 
and opposite closed arms of the same size, but with 
40-cm-high walls. The arms were connected by a 
central square (10 × 10 cm) and, thus, formed a plus 
sign. The apparatus was elevated 50 cm above the 
floor. Each rat was placed in the central square of the 
plus-maze set facing an enclosed arm. The time spent 
in the enclosed and open arms was scored for 5 min. 
An arm entry was defined as an animal entered the arm 
with all four feet, and the number of entries into the 
open and enclosed arms was scored [23]. The value 
of total time spent in the open arm/total value)∙100% 
was, with obvious natural reservations, considered an 
anxiety index, and (number of closed arm entries/total 
value)∙100% was measured as an index of locomotor 
activity.
Statistical Analysis. All results are presented below 
as means ± s.e.m. for seven animals per group. A two-
tailed Student’s t-test was used to compare the mean 
frequencies of the behaviors between groups. Some 
data were assessed by analysis of variance (ANOVA). 
The subsegment post­hoc analyses (the LSD test) were 
performed for assessing specific group comparisons 
and differences, where P < 0.05 was considered an 
index of statistical significance. Calculations were 
performed using the SPSS (version 19) statistical 
package. 
RESULTS
Treatment of Young and Mature Rats with Morphine 
and/or DEX. As is shown in Fig. 1A, the percentage 
of time in the open arms was dramatically greater 
(P < 0.001) after morphine (5 mg/kg) injections and 
also after dexamethasone (DEX) (1 mg/kg) (P < 0.001) 
in the young group. In the adult group, this index was 
also increased (P < 0.05) by morphine (lesser than in 
young animals) and dexamethasone (P < 0.001), which 
showed anxiolytic effects of these agents. Also there 
was a significant difference between time in open arms 
between the control groups (P < 0.05) and between 
the morphine-receiving groups of young and adult rats 
(P < 0.05). This means that the anxiety level in adult 
rats is greater, and that morphine is noticeably more 
effective in young rats.
Closed arm entries as the index of locomotor 
activity decreased in young rats that received morphine 
(5 mg/kg) or DEX (1 mg/kg) in comparison with the 
control group (P < 0.05), (Fig. 1B). 
Injections of both 5 mg/kg morphine and 1 mg/kg 
dexamethasone dramatically (more than two times) 
increased the percentage  of time spent by young rats 
in the open arms of the testing set (P < 0.001 in both 
cases). Introductions of these agents exerted similar 
affects also on mature animals, but it should be 
mentioned that the intensity of such influence on these 
rats was much stronger than that on young individuals 
(P < 0.001 and P < 0.05, respectively). It should also 
be emphasized that the normalized mean time spent by 
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F i g. 1. Effects of morphine (morph, 5 mg/kg) and dexamethasone (DEX, 1 mg/kg) on anxiety (A) and locomotor activity indices (B) in rats 
of different age. Diagrams of normalized values, %, of time spent by the animals in open arms of the testing set (A) and number of entries 
in closed arms (B) in young (1-month-old, Y) and mature (3-month-old, M) rats. *P < 0.05, ***P < 0.001 compared to the rats receiving 
saline (control, C); #P < 0.05 in comparisons between young and mature rats; +P < 0.05 in comparisons between young and mature rats 
receiving morphine, n = 7 in all cases. 
Р и с. 1. Впливи морфіну (% мг/кг) та дексаметазону (1 мг/кг) на індекси тривожності (А) та локомоторної  активності (В) у щурів 
різного віку. 
F i g. 2. Effects of co-injections of 5 mg/kg morphine and 1 mg/kg dexamethasone in young and mature rats. Designations are similar to 
those in Fig. 1. **P < 0.01 in comparison with the morphine (5 mg/kg)-injected group. 
Р и с. 2. Впливи комбінованих ін’єкцій 5 мг/кг морфіну та 1 мг/кг дексаметазону на молодих та зрілих щурів.
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F i g. 3. Effects of 5 mg/kg morphine in the presence of RU486 (20 mg/kg) in young and mature rats. Designations are similar to those in 
Figs. 1 and 2. ***P < 0.001 in comparison with the morphine (5 mg/kg)-injected group.
Р и с. 3. Впливи ін’єкцій 5 мг/кг морфіну в присутності RU486 (20 мг/кг) на молодих та зрілих щурів.
F i g.4. Effects of 1 mg/kg dexamethasone in the presence of naloxone (nal, 2 mg/kg) in young and mature rats. Designations are similar to 
those in Figs. 1-3.***P < 0.001 in comparison with the DEX (1 mg/kg)-injected group.
Р и с. 4. Впливи 1 мг/кг дексаметазону в присутності налоксону (2 мг/кг) на молодих та зрілих щурів.
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young rats in the open arms under control conditions 
(saline injections) was significantly greater than the 
respective value in mature (3-month-old) individuals 
(Fig. 1A). This means that the anxiety level in mature 
rats is, in general, greater than in young ones, and 
morphine is more effective in decreasing this index 
in the latter age group. Injections of the above-
mentioned drugs induced mild (but significant) 
decreases in the index of locomotor activity in young 
rats but exerted nearly no effect on this index in elder 
(mature) animals (Fig. 1B). Combined injections 
of morphine and DEX (1 mg/kg) evoked anxiolytic 
effects in young rats nearly similar to those provided 
by isolated applications of morphine. In mature rats, 
such combined injections induced much more intense 
effects with this respect than introductions of morphine 
alone  (P < 0.001) (Fig. 2A). Closed arm entries 
(characterizing the intensity of locomotor activity) 
did not change at such a combination (in comparison 
with “pure” morphine effects in young animals). In 
mature ones, the respective index moderately but 
significantly increased at the above combination 
(P < 0.001) (Fig. 2B).       
There were significant differences in the percentage 
of time in the open arms and that of the closed arm 
entries (or locomotor activity) between the group that 
received RU486 (20 mg/kg) + morphine (5 mg/kg) in 
comparison with the only-morphine (5 mg/kg) group, 
but this was observed exclusively in young rats (P < 
< 0.001). At the same time there were no differences 
between these two groups of mature animals (Fig. 3). 
This means that the anxiolytic effect of morphine was 
prevented by RU486 only in immature rats. A mild 
(whereas significant) increase in the locomotor activity 
index was found in morphine + RU486-injected young 
rats, and such a difference was absent in mature animals 
(Fig. 3B). There were significant differences in the 
percentage of time in the open arms and in the index of 
locomotor activity in young rats that received 2 mg/kg 
naloxone + 1 mg/kg DEX in comparison with the DEX 
(1 mg/kg) group of such animals (P < 0.001). At 
the same time, there were no significant differences 
between these two groups in mature rats (Fig. 4A, B).
DISCUSSION
Our study showed that, in general, the level of 
anxiety is higher in older (mature) rats, which is in 
agreement with the data of previous studies of age-
related changes in the anxiety indexes in male rats in 
the elevated plus maze and light/dark tests [23-25]. 
Our results also showed that morphine (5 mg/kg) 
and also dexamethasone (1 mg/kg) induced significant 
increases in the percentage of time in the open arms, 
which clearly indicates an anxiolytic effect for 
both agents (Fig. 1). In young rats, morphine and 
dexamethasone noticeably reduced locomotor activity, 
and this was not observed in adult rats.  Previous 
studies showed that the above doses of morphine and 
dexamethasone provide anxiolytic effects in adult 
(mature) animals, which is comparable with our results 
[6, 7, 25]. There were significant differences between 
the results of co-administration of morphine and 
DEX, in comparison with those of morphine alone, on 
anxiety behavior in adult rats, but this was not found 
in young rats. In mature rats, morphine co-injected 
with DEX increased the locomotor activity (Fig. 2B). 
In previous studies, morphine was shown to induce 
clear corticosterone responses at doses of 20 or 
30 mg/kg, whereas no significant effect of morphine 
on the corticosterone levels was found at doses of 5 or 
10 mg/kg [26]. These results are consistent with our 
results; it seems that a combination of two antianxiety 
drugs was partly related to the change in locomotor 
activities. Out results also showed that morphine in 
the presence of RU486 increased the anxiety level 
with a decrease in the percentage of time spent in the 
open arms in young rats. This fact was indicative of 
the increase in locomotor activity in these animals, 
but such an effect was absent in adult rats (Fig. 3). It 
seems that RU486 prevented noticeably the anxiolytic 
effect of morphine. It was shown that the inhibitory 
effect of RU486 is dose-dependent and linked to a 
decrease in the affinity of labeled dihydromorphine 
to µ-opioid receptors [27]. Kinetic experiments 
demonstrated that RU486 induces a decrease in the 
association rate constant of dihydromorphine [27]. 
RU486 also was proved to be able to dissociate the 
dihydromorphine-µ-opioid receptor complex [27]. 
RU486 inhibits binding of labeled dihydromorphine to 
µ-opioid receptors present in membrane preparations 
derived from the rat and mouse brains, as well as in 
human neuroblastoma cells [27].
In addition, it was demonstrated that impairment 
of the receptor-dependent glucocorticoid action in 
the neonatal brain resulted in longer-lasting hormonal 
stress responses, reduction of locomotion phenomena, 
and an increase in the anxiety level in adulthood [28]. 
This discordance of the results with our data on adult 
rats can be related (at least partly) to differences in 
the protocols. As was shown in our study, naloxone 
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inhibited the anxiolytic effect of dexamethasone and 
increased locomotor activity in young rats, but this was 
not observed in mature animals (Fig. 4). This result is 
in agreement with that of the study where no detectable 
increases in the plasma cortisol levels were found 
following both naloxone and saline administrations; 
this finding was indicative of effective opioid 
blockade at the level of hypothalamic-pituitary units 
[6, 29]. This finding also indicates the involvement 
of a naloxone-sensitive pathway in mediation of the 
influences of glucocorticoids on anxiety. 
There are two possible explanations for interaction 
between dexamethasone and naloxone in the anxiety 
state. First, it is likely that dexamethasone activates 
the endogenous opioid system, and the latter mediates 
the respective influences on anxiety. Although, there 
is some evidence indicating that the effects of DEX on 
such phenomena as analgesia and emotional memory 
are mediated (at least in part) by the endogenous opioid 
system [30]. However,  there are, to our knowledge, no 
reports in the literature concerning such mediation of 
anxiety. Another explanation for these results might 
be that naloxone interacts with stress- and anxiety-
induced glucocorticoids (or dexamethasone) in the 
plasma membranes of target neurons in the brain [31]. 
Therefore, our study showed that both opioid and 
glucocorticoid receptor agonists are effective to reduce 
the anxiety level in young and mature rats. Blocking 
of these receptors influences the above level in young 
rats noticeably stronger than that in adults this fact 
may be related to considerable dissimilarities of the 
neural and hormonal system activities in young and 
mature animals. 
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МОДУЛЯТОРНІ ВПЛИВИ ГЛЮКОКОРТИКОЇДНОЇ ТА 
ОПІОЇДНОЇ СИСТЕМ НА ПОВ’ЯЗАНУ З ТРИВОЖНІСТЮ 
ПОВЕДІНКУ МОЛОДИХ ТА ЗРІЛИХ ЩУРІВ 
1 Університет Шахід Чамран, Ахваз (Іран).
Р е з ю м е
Враховуючи недостатню інформацію щодо взаємних 
впливів глюкокортикоїдів та опіоїдної системи на поведінку 
та залежність відповідних ефектів від віку, ми вивчали 
впливи введення 1 мг/кг дексаметазону та 20 мг/кг RU486 
(агоніста та антагоніста глюкокортикоїдних рецепторів), а 
також 5 мг/кг морфіну та 20 мг/кг налоксону (агоніста та 
антагоніста опіоїдної системи) на рівень тривожності в тесті 
підвищеного лабіринту у молодих та зрілих щурів-самців. 
Нормовані значення часу, проведеного у відкритих рукавах 
лабіринту, та аналогічні значення кількості входів до 
закритих рукавів розглядались як індекси рівня тривожності 
та інтенсивності локомоторної активності відповідно. 
Уведення 5 мг/кг морфіну та 1 мг/кг дексаметазону 
зумовлювали значні анксіолітичні ефекти як у молодих, так і 
у зрілих щурів; дані агенти істотно знижували локомоторну 
активність тільки у молодих тварин. RU486 міг усувати 
анксіолітичні ефекти морфіну. Анксіолітичний вплив 
дексаметазону гальмувався налоксоном у молодих щурів, 
але цього не спостерігалось у зрілих тварин. Такі результати 
свідчать про існування істотної взаємодії глюкокортикоїдів 
та опіоїдної системи в їх функції опосередкування рівня 
тривожності та про значну залежність відповідних ефектів 
від віку. 
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